DRG Diagnostic developed two SARS-CoV-2 Antibody assays: 1) SARS-CoV-2 (RBD) Total Ab ELISA 2) SARS-CoV-2 (RBD) IgG ELISA
DRG® develops and introduces Soluble Transferrin. DRG International receives the MDSAP Certification.
DRG® develops and introduces Salivary Hepcidin.
Dr. Cyril E. Geacintov, founder and owner of DRG International, passes away at the age of 87. Mrs. Elke Geacintov takes over as the President & CEO of DRG International. DRG® receives the ISO 13485 Certification.
NEW WEBSITE LAUNCH !
Small scale manufacturing and R&D begins in the DRG Headquarters in USA, managed by several additional staff
Introduction for distribution of the DRG:HYBRiD-XLTM continues through international approval processes with great success Continued development of Elisa kits to utilize with DRG:HYBRiD-XLTM Expanded growth in several international markets including China
New US Headquarters established in Springfield, New Jersey with expanded laboratory space and distribution DRG:HYBRiD-XLTM continues through international approval processes with great success
Introduction of CA 72-4 (FDA Registration now underway)
United States Patent Office issues two more patents to DRG International for development of Hepcidin diagnostic kits DRG International unveils the DRG: HYBRiD-XL® fully-automatic, random access analyzer for immunoassays and clinical chemistry to revolutionize laboratory procedures!
Introduction to market of DRG® Renin, PLGF, Afamin, Anti-Amyloid, Cripto-1, CYR61, L1-Cam, and NOV Elisa kits
United States Patent Office issues two patents to DRG International for development of Hepcidindiagnostic kits
DRG® develops Tumor Markers, CA 72-4, CA 125, CA 15-3, CA 19-9, Cyfra21-1 and introduces Corticosterone andEstrone ELISAs
DRG® develops and introduces the first worldwide Assay for the measurement of Hepcidin DRG® acquires Novum-Diagnostics in Dietzenbach and takes over production of more than 70 ELISAs for Infectious diseases in the DRG-Novum Branch Lab
DRG® develops and introduces various Saliva -and DHEA –ELISAs
DRG® develops and Introduces IGF1, IL-6,Cortisol- Saliva, Androstenedione ELISAs DRG® received certification for QM-System EN ISO9001:1994 DNVon October 27th Dade BehringTechnology is transferred to DRG® production of C5a and PAP – ELISAs
DRG® develops and introduces Insulin, PAPP-A, and TGFßII ELISAs
DRG® moves to a new building in Marburg, Germany DRG Instruments GmbH celebrates 25 years in Marburg, Germany
DRG® develops and introduces Leptin, TGFß,and ß-HCG ELISAs
DRG® develops and introduces Free Estriol ELISA
DRG® develops and Introduces the first worldwide, non-radioactive C-Peptide and Proinsulin Assays
DRG® develops and introduces DHEA-S, Progesterone, Testosterone, PMSG, and βGH ELISAs DRG® opens DRG Diagnostics Branch Office in Berlin, Germany
DRG Techsystemsis founded in Moscow, Russa DRG® develops and introduces 17-OH-Progesterone ELISA
DRG Sp.O.O. is founded in Brno, Czechoslovakia (Czech Rep.) DRG® develops and introduces AFP, HCG, FSH, Prolactin and LH
DRG Biomed founded in St. Petersburg, Russia DRG® launches first neonatal entry of DRG®-ELISA:HPL
DRG MEDTEK founded in Warsaw, Poland DRG® begins R&D and ELISA production in Marburg, Germany
DRG AG founded in Zürich,Switzerland
DRG® begins in-house R&D Operations
DRG® expands in Eastern and Western Europe
DRG® introduces the Mechanical Heart Valve on European Cardiac Surgery Market
DRG Instruments GmbH moves to Marburg, Germany
Distribution of RIA`s in Germany begins DRG Instruments GmbH is founded in Munich, Germany
DRG International, Inc. was founded by Dr. C.E. Geacintov in New Jersey, USA DRG® enters market in Europe, USSR, Poland and Yugoslavia.